Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer

Author(s): Petros Sountoulides*, Evangelos N. Symeonidis, Nikolaos Pyrgidis and Luca Cindolo

Volume 21, Issue 15, 2020

Page: [1512 - 1514] Pages: 3

DOI: 10.2174/138945012115201102115645

« Previous Next »
[1]
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20(6): 327-36.
[http://dx.doi.org/10.1007/s00345-002-0301-4] [PMID: 12811491]
[2]
Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the international continence society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167-78.
[http://dx.doi.org/10.1002/nau.10052] [PMID: 11857671]
[3]
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50(6): 1306-14.
[http://dx.doi.org/10.1016/j.eururo.2006.09.019] [PMID: 17049716]
[4]
Lawrence JM, Lukacz ES, Nager CW, Hsu JW, Luber KM. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol 2008; 111(3): 678-85.
[http://dx.doi.org/10.1097/AOG.0b013e3181660c1b] [PMID: 18310371]
[5]
Nitti VW. Clinical impact of overactive bladder. Rev Urol 2002; 4(Suppl. 4): S2-6.
[PMID: 16986018]
[6]
Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 2009; 15(4)(Suppl.): S90-7.
[PMID: 19355803]
[7]
Wadie BS. Management of refractory OAB in the non-neurogenic patient. Curr Urol Rep 2014; 15(9): 438.
[http://dx.doi.org/10.1007/s11934-014-0438-x] [PMID: 25015301]
[8]
Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT. Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 2009; 10: 8.
[http://dx.doi.org/10.1186/1471-2296-10-8] [PMID: 19166611]
[9]
Gormley EA, Lightner DJ, Faraday M, Vasavada SP, Association AU. American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015; 193(5): 1572-80.
[http://dx.doi.org/10.1016/j.juro.2015.01.087] [PMID: 25623739]
[10]
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54(3): 543-62.
[http://dx.doi.org/10.1016/j.eururo.2008.06.047] [PMID: 18599186]
[11]
Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014; 191(4): 1003-8.
[http://dx.doi.org/10.1016/j.juro.2013.10.046] [PMID: 24140548]
[12]
Lucas MG, Bosch RJ, Burkhard FC, et al. European Association of Urology. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol 2012; 62(6): 1118-29.
[http://dx.doi.org/10.1016/j.eururo.2012.09.023] [PMID: 23040204]
[13]
van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus” in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. Rev Infect Dis 1979; 1(4): 701-19.
[http://dx.doi.org/10.1093/clinids/1.4.701] [PMID: 399378]
[14]
Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou EC. Botulinum toxin A for the Treatment of Overactive Bladder. Toxins (Basel) 2016; 8(3)e59
[http://dx.doi.org/10.3390/toxins8030059] [PMID: 26938559]
[15]
Ellsworth P, Travis M. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Urol Nurs 2014; 34(4): 165-71.
[http://dx.doi.org/10.7257/1053-816X.2014.34.4.165] [PMID: 25233617]
[16]
Cui Y, Zhou X, Zong H, Yan H, Zhang Y. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. Neurourol Urodyn 2015; 34(5): 413-9.
[http://dx.doi.org/10.1002/nau.22598] [PMID: 24676791]
[17]
Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl) 2015; 128(7): 963-8.
[http://dx.doi.org/10.4103/0366-6999.154318] [PMID: 25836619]
[18]
Palleschi G, Mosiello G, Iacovelli V, et al. Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement. Neurourol Urodyn 2018; 37(3): 904-15.
[http://dx.doi.org/10.1002/nau.23391] [PMID: 28877353]
[19]
Giannantoni A, Carbone A, Carone R, et al. Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. World J Urol 2017; 35(2): 299-306.
[http://dx.doi.org/10.1007/s00345-016-1847-x] [PMID: 27229889]
[20]
Leu R, Stearns GL. Complications of Botox and their Management. Curr Urol Rep 2018; 19(11): 90.
[http://dx.doi.org/10.1007/s11934-018-0844-6] [PMID: 30194497]
[21]
Liao CH, Wang CC, Jiang YH. Intravesical onabotulinumtoxina injection for overactive bladder patients with frailty, Medical comorbidities or prior lower urinary tract surgery. Toxins (Basel) 2016; 8(4): 91.
[http://dx.doi.org/10.3390/toxins8040091] [PMID: 27023603]
[22]
Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler GB Jr, Walston JD. Interventions on frailty working group. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004; 52(4): 625-34.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52174.x] [PMID: 15066083]
[23]
White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 2008; 180(6): 2522-6.
[http://dx.doi.org/10.1016/j.juro.2008.08.030] [PMID: 18930481]
[24]
Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol 2013; 189(5): 1804-10.
[http://dx.doi.org/10.1016/j.juro.2012.11.089] [PMID: 23178902]
[25]
Komesu YM, Amundsen CL, Richter HE, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications Am J Obstet Gynecol 2018; 218(1): 111 e1-e9.
[http://dx.doi.org/10.1016/j.ajog.2017.10.006]
[26]
Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. Neurourol Urodyn 2014; 33(8): 1235-9.
[http://dx.doi.org/10.1002/nau.22494] [PMID: 24115083]
[27]
Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int 2015; 116(Suppl. 3): 61-5.
[http://dx.doi.org/10.1111/bju.13110] [PMID: 26176660]
[28]
Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010; 58(6): 919-26.
[http://dx.doi.org/10.1016/j.eururo.2010.09.007] [PMID: 20864251]
[29]
Miotla P, Futyma K, Cartwright R, et al. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. Int Urogynecol J Pelvic Floor Dysfunct 2016; 27(3): 393-8.
[http://dx.doi.org/10.1007/s00192-015-2839-x] [PMID: 26364180]
[30]
Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 2016; 25(2): 179-87.
[http://dx.doi.org/10.1002/pds.3920] [PMID: 26635276]
[31]
Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J Pelvic Floor Dysfunct 2017; 28(6): 845-50.
[http://dx.doi.org/10.1007/s00192-016-3212-4] [PMID: 27889830]
[32]
Gamé X, Mouracade P, Chartier-Kastler E, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 2009; 5(3): 156-64.
[http://dx.doi.org/10.1016/j.jpurol.2009.01.005] [PMID: 19264554]
[33]
Cheng T, Shuang WB, Jia DD, et al. Efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2016; 11(7)e0159307
[http://dx.doi.org/10.1371/journal.pone.0159307] [PMID: 27463810]
[34]
Karsenty G, Baverstock R, Carlson K, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract 2014; 68(6): 731-42.
[http://dx.doi.org/10.1111/ijcp.12360] [PMID: 24472109]
[35]
Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011; 60(4): 784-95.
[http://dx.doi.org/10.1016/j.eururo.2011.07.001] [PMID: 21782318]
[36]
Apostolidis A, Rahnama’i MS, Fry C, Dmochowski R, Sahai A. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. Neurourol Urodyn 2016; 35(2): 293-8.
[http://dx.doi.org/10.1002/nau.22797] [PMID: 26872570]
[37]
Zhang R, Xu Y, Yang S, Liang H, Zhang Y, Liu Y. OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol 2015; 41(2): 207-19.
[http://dx.doi.org/10.1590/S1677-5538.IBJU.2015.02.05] [PMID: 26005961]
[38]
Jo JK, Kim KN, Kim DW, Kim YT, Kim JY, Kim JY. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol 2018; 36(2): 305-17.
[http://dx.doi.org/10.1007/s00345-017-2121-6] [PMID: 29124347]
[39]
Ni J, Wang X, Cao N, Si J, Gu B. Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis. Neurourol Urodyn 2018; 37(2): 542-53.
[http://dx.doi.org/10.1002/nau.23354] [PMID: 28745818]
[40]
Araklitis G, Cardozo L. Safety issues associated with using medication to treat overactive bladder. Expert Opin Drug Saf 2017; 16(11): 1273-80.
[http://dx.doi.org/10.1080/14740338.2017.1376646] [PMID: 28889761]
[41]
Sun Y, Luo D, Tang C, Yang L, Shen H. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol 2015; 47(11): 1779-88.
[http://dx.doi.org/10.1007/s11255-015-1125-7] [PMID: 26433883]
[42]
López Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodríguez A, Moreno Bencardino C. Management of overactive bladder with OnabotulinumtoxinA: Systematic review and meta-analysis. Urology 2017; 100: 53-8.
[http://dx.doi.org/10.1016/j.urology.2016.10.026] [PMID: 27789302]
[43]
Arruda RM, Takano CC, Girão MJBC, Haddad JM, Aleixo GF, Castro RA. Treatment of non-neurogenic overactive bladder with OnabotulinumtoxinA: Systematic review and meta-analysis of prospective, randomized, placebo-controlled clinical trials. Rev Bras Ginecol Obstet 2018; 40(4): 225-31.
[http://dx.doi.org/10.1055/s-0038-1642631] [PMID: 29747213]
[44]
Leitner L, Sammer U, Walter M, et al. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep 2016; 6: 33197.
[http://dx.doi.org/10.1038/srep33197] [PMID: 27616488]
[45]
Harris MA, Harding C, Fulford S, Whiteway J. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 2011; 107(7): 1165.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10216.x] [PMID: 21438980]
[46]
Houman J, Moradzadeh A, Patel DN, Asanad K, Anger JT, Eilber KS. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. Int Urogynecol J Pelvic Floor Dysfunct 2019; 30(5): 701-4.
[http://dx.doi.org/10.1007/s00192-018-3721-4] [PMID: 30074062]
[47]
Ginsberg D, Cruz F, Herschorn S, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 2013; 30(9): 819-33.
[http://dx.doi.org/10.1007/s12325-013-0054-z] [PMID: 24072665]
[48]
Solinsky R, Svircev JN, James JJ, Burns SP, Bunnell AE. A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries. J Spinal Cord Med 2016; 39(6): 713-9.
[http://dx.doi.org/10.1080/10790268.2015.1118186] [PMID: 26838482]
[49]
Peyronnet B, Sanson S, Amarenco G, et al. Membres du GENULF (Groupe d’étude de neuro-urologie de langue française) et du comité de neuro-urologie de l’AFU (Association française d’urologie). Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey Prog Urol 2015; 25(17): 1219-24.
[http://dx.doi.org/10.1016/j.purol.2015.07.006] [PMID: 26318394]
[50]
Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21(3): 189-92.
[PMID: 16901418]
[51]
Baron M, Peyronnet B, Aublé A, et al. Long-term discontinuation of botulinum toxin a intradetrusor injections for neurogenic detrusor overactivity: A multicenter study. J Urol 2019; 201(4): 769-76.
[http://dx.doi.org/10.1016/j.juro.2018.10.012] [PMID: 30359679]
[52]
Joussain C, Popoff M, Phé V, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn 2018; 37(2): 799-806.
[http://dx.doi.org/10.1002/nau.23352] [PMID: 28745807]
[53]
Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19(Suppl. 8): S92-S100.
[http://dx.doi.org/10.1002/mds.20022] [PMID: 15027060]
[54]
Makovey I, Davis T, Guralnick ML, O’Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 2011; 30(8): 1538-40.
[http://dx.doi.org/10.1002/nau.21150] [PMID: 21826718]
[55]
Abrar M, Stroman L, Malde S, Solomon E, Sahai A. Predictors of poor response and adverse events following botulinum Toxin-A for refractory idiopathic overactive bladder. Urology 2020; 135: 32-7.
[http://dx.doi.org/10.1016/j.urology.2019.08.054] [PMID: 31626856]
[56]
Dressler D, Pan L, Adib Saberi F. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Transm (Vienna) 2018; 125(10): 1481-6.
[http://dx.doi.org/10.1007/s00702-018-1911-3] [PMID: 30066275]
[57]
Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol 1997; 147(1): 96-102.
[http://dx.doi.org/10.1006/exnr.1997.6580] [PMID: 9294406]
[58]
Denys P, Le Normand L, Ghout I, et al. VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012; 61(3): 520-9.
[http://dx.doi.org/10.1016/j.eururo.2011.10.028] [PMID: 22036776]
[59]
Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 2017; 9(1): 3-10.
[http://dx.doi.org/10.1177/1756287216672180] [PMID: 28042308]
[60]
Kennelly M, Dmochowski R, Schulte-Baukloh H, et al. 191622-094 Investigators. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourol Urodyn 2017; 36(2): 368-75.
[http://dx.doi.org/10.1002/nau.22934] [PMID: 26607743]
[61]
Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev Neurother 2017; 17(5): 487-94.
[http://dx.doi.org/10.1080/14737175.2017.1262258] [PMID: 27852103]
[62]
Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2019; 11(9)E491
[http://dx.doi.org/10.3390/toxins11090491] [PMID: 31454941]
[63]
Traini C, Del Popolo G, Faussone-Pellegrini MS, Guasti D, Catarinicchia S, Vannucchi MG. Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies. J Cell Mol Med 2019; 23(6): 4076-87.
[http://dx.doi.org/10.1111/jcmm.14294] [PMID: 30945429]
[64]
Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014; 65(5): 981-90.
[http://dx.doi.org/10.1016/j.eururo.2013.10.033] [PMID: 24239446]
[65]
Wu SJ, Xu YQ, Gao ZY, et al. Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis. Ren Fail 2019; 41(1): 937-45.
[http://dx.doi.org/10.1080/0886022X.2019.1655448] [PMID: 31599184]
[66]
Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 2002; 83(1): 129-38.
[http://dx.doi.org/10.1053/apmr.2002.26605] [PMID: 11782843]
[67]
Apostolidis A, Cameron AP. Neurourological management after failed intradetrusor OnabotulinumtoxinA injections. Eur Urol Focus 2019; 6: 814-6.
[http://dx.doi.org/10.1016/j.euf.2019.10.003] [PMID: 31735594]
[68]
Finazzi-Agrò E, Topazio L, Perugia C, et al. The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study. Spinal Cord 2013; 51(8): 637-41.
[http://dx.doi.org/10.1038/sc.2013.42] [PMID: 23689390]
[69]
Doherty A, Hennessey DB, Onggo JR, Ranasinghe W, Gani J. Modifications to Botulinum toxin A delivery in the management of detrusor overactivity recalcitrant to initial injections: a review. World J Urol 2019; 37(5): 891-8.
[http://dx.doi.org/10.1007/s00345-018-2456-7] [PMID: 30140945]
[70]
Cui Y, Wang L, Liu L, et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 2013; 91(4): 429-38.
[http://dx.doi.org/10.1159/000351037] [PMID: 23970316]
[71]
Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184(6): 2416-22.
[http://dx.doi.org/10.1016/j.juro.2010.08.021] [PMID: 20952013]
[72]
Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol 2013; 31(6): 1469-74.
[http://dx.doi.org/10.1007/s00345-012-0984-0] [PMID: 23160758]
[73]
Li GP, Wang XY, Zhang Y. Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis. Int Neurourol J 2018; 22(4): 275-86.
[http://dx.doi.org/10.5213/inj.1836118.059] [PMID: 30599499]
[74]
Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005; 5(3): 274-9.
[http://dx.doi.org/10.1016/j.coph.2004.12.006] [PMID: 15907915]
[75]
Ferrari A, Manca M, Tugnoli V, Alberto L. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol 2018; 33(1): 7-18.
[http://dx.doi.org/10.11138/FNeur/2018.33.1.007] [PMID: 29633692]
[76]
Peyronnet B, Castel-Lacanal E, Manunta A, et al. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin. Int J Urol 2015; 22(12): 1160-5.
[http://dx.doi.org/10.1111/iju.12950] [PMID: 26391575]
[77]
Bottet F, Peyronnet B, Boissier R, et al. Groupe d’Etude de Neuro-Urologie de Langue Française (GENULF) and the committee of NeuroUrology of the French Association of Urology (AFU). Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourol Urodyn 2018; 37(1): 291-7.
[http://dx.doi.org/10.1002/nau.23291] [PMID: 28431196]
[78]
Peyronnet B, Roumiguié M, Castel-Lacanal E, et al. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity. Neurourol Urodyn 2016; 35(2): 267-70.
[http://dx.doi.org/10.1002/nau.22712] [PMID: 25524826]
[79]
Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel) 2016; 8(3)E65
[http://dx.doi.org/10.3390/toxins8030065] [PMID: 26959061]
[80]
Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14(6): 424-6.
[http://dx.doi.org/10.1007/s00192-003-1099-3] [PMID: 14677005]
[81]
Conte A, Giannantoni A, Gubbiotti M, et al. Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. Toxins (Basel) 2015; 7(9): 3424-35.
[http://dx.doi.org/10.3390/toxins7093424] [PMID: 26343721]
[82]
Schneider MP, Gross T, Bachmann LM, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: A systematic review. Eur Urol 2015; 68(5): 859-67.
[http://dx.doi.org/10.1016/j.eururo.2015.07.001] [PMID: 26194043]
[83]
Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 2010; 58(6): 865-74.
[http://dx.doi.org/10.1016/j.eururo.2010.09.024] [PMID: 20934242]
[84]
Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183(4): 1438-43.
[http://dx.doi.org/10.1016/j.juro.2009.12.036] [PMID: 20171677]
[85]
Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184(5): 2001-6.
[http://dx.doi.org/10.1016/j.juro.2010.06.113] [PMID: 20850833]
[86]
Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Invest 2013; 75(1): 46-52.
[http://dx.doi.org/10.1159/000343756] [PMID: 23171636]
[87]
Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3): 1055-61.
[http://dx.doi.org/10.1016/j.juro.2009.05.045] [PMID: 19616802]
[88]
Hoag N, Plagakis S, Pillay S, Edwards AW, Gani J. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. Neurourol Urodyn 2017; 36(5): 1377-81.
[http://dx.doi.org/10.1002/nau.23117] [PMID: 27612039]
[89]
Smits MA, Oerlemans D, Marcelissen TA, Van Kerrebroeck PE, De Wachter SG. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. J Urol 2013; 190(6): 2148-52.
[http://dx.doi.org/10.1016/j.juro.2013.07.017] [PMID: 23872028]
[90]
Gross T, Schneider MP, Bachmann LM, et al. Transcutaneous electrical nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol 2016; 69(6): 1102-11.
[http://dx.doi.org/10.1016/j.eururo.2016.01.010] [PMID: 26831506]
[91]
Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review. Neurourol Urodyn 2018; 37(2): 528-41.
[http://dx.doi.org/10.1002/nau.23351] [PMID: 28731583]
[92]
Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol 2016; 5(1): 117-26.
[PMID: 26904417]
[93]
Hu M, Lai S, Zhang Y, Liu M, Wang J. Sacral neuromodulation for lower urinary tract dysfunction in spinal cord injury: A systematic review and meta-analysis. Urol Int 2019; 103(3): 337-43.
[http://dx.doi.org/10.1159/000501529] [PMID: 31362290]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy